Literature DB >> 16010586

T-Cell activation by t(9;22) acute lymphoblastic leukemia-derived dendritic-like cells is associated with increased tapasin expression.

Jonathan A Claus1, Michael T Brady, Jaewoo Lee, Kathleen A Donohue, Sheila N Sait, Soldano Ferrone, Meir Wetzler.   

Abstract

Dendritic-like cells from t(9;22) acute lymphoblastic leukemia (ALL) blasts can activate T cells, while the original unmodified leukemic blasts cannot. To determine whether these functional differences were associated with differences in antigen-processing machinery (APM) component expression, we have measured the level of APM component expression in unmodified blasts and ALL-derived dendritic-like cells. Seven t(9;22) ALL patient samples and one cell line were studied for APM component expression utilizing a unique panel of recently developed monoclonal antibodies and a recently developed intracellular staining technique. In addition, the HLA class I antigen cell surface expression was measured. HLA class I antigens were similarly expressed on the unmodified blasts and on the autologous dendritic-like cells. Intracellular HLA class I antigen and tapasin expression (P=0.03 for both) were upregulated in all t(9;22) ALL-derived dendritic-like cells, in comparison to the unmodified blasts. These results provide a potential mechanism for the ability of t(9;22) ALL-derived dendritic-like cells to induce T-cell activation and, suggest that tapasin upregulation may serve as a marker to standardize and monitor the quality of the dendritic-like cells used in immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16010586     DOI: 10.1007/s00262-005-0012-y

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  1 in total

1.  Interferon-γ secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells.

Authors:  Michael T Brady; Jaewoo Lee; Soldano Ferrone; Eunice S Wang; Meir Wetzler
Journal:  Leuk Res       Date:  2010-10-12       Impact factor: 3.156

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.